Answers are grounded in this paper and cite their sources.
Introduction A key challenge in early-stage clinical development of treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) is gaining meaningful proof-of-concept insights within short trial durations. Use of biomarkers/non-invasive tests (NITs) in this setting is limited by insufficient evidence. This review critically analyzes short-term changes in liver-related biomarkers/NITs in MASH, specifically examining evidence linking these changes to histologic and clinical outcomes to support early drug development. Methods This systematic scoping review was conducted in accordance with the JBI methodology and PRISMA-ScR. PubMed, Embase, and the Cochrane Library were searched for: (1) preclinical/clinical studies reporting biomarker data for monitoring disease progression in MASLD/MASH (for human studies, only patients aged ≥18 years included); and (2) reporting data ≤24 weeks. The search strategy included fibrosis- and inflammation-related terms to identify biomarkers relevant to fibro-inflammatory disease modification following short-term therapeutic intervention. Results Of the 493 records screened, 21 studies met the final inclusion criteria. Of these 21 studies, statistically significant changes in liver-related biomarkers over time were reported in 16 studies, with 405 individual biomarkers identified across all studies. Aside from clinical-practice-established non-specific biomarkers (alanine transaminase, aspartate aminotransferase, and gamma-glutamyl transferase), the most frequently reported biomarkers with significant changes were liver fat and liver stiffness (both measured through imaging), N-terminal type III collagen propeptide, and enhanced liver fibrosis score. Liver stiffness was also the only biomarker to be associated with other biomarkers, histology changes, or clinical outcomes in more than one study. Conclusion Despite the large number of biomarkers identified here, there is limited evidence to support the utility of these biomarkers in early clinical trials for decision making. Future studies are needed to identify non-invasive biomarkers that reliably identify early signals of disease modification, which translate to clinically meaningful improvements in MASH disease progression.
No takes yet. Share an insight, caveat, or question.
Ludvigsen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: